Key Points
The transaction involved 173,148 shares sold at a weighted average price of $125.47, totaling approximately $21.7 million.
This disposition represents 39% of the CEO's direct common stock holdings in the company.
The filing confirms all transacted shares were held directly.
Encompass Health Corporation (NYSE:EHC) President and CEO Mark J. Tarr reported a sale of about 173,000 shares of common stock on August 10, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction date | August 10, 2026 |
| Shares sold | 173,148 |
| Transaction value | $21.7 million |
| Post-transaction shares (directly held) | 267,814 |
| Post-transaction value | $33.69 million |
Transaction value based on SEC Form 4 weighted average sale price ($125.47); post-transaction value based on the August 10 market close ($125.81).
Key questions
- What were the specific execution details for this transaction?
The shares were sold in multiple transactions at prices ranging from $124.93 to $126.22, with the reporting person providing weighted average data for two distinct price bands in the filing. - How does this sale impact the CEO's overall equity stake?
The disposition reduced Tarr's direct common stock position by 39%, though he maintains a significant remaining stake of 268,000 shares valued at more than $33 million. - What is the broader operational context for Encompass Health?
Headquartered in Birmingham, the company operates across two primary divisions, Inpatient Rehabilitation and Home Health and Hospice, and currently maintains a market capitalization of $12.5 billion. - Does the insider have any remaining indirect beneficial interest?
No, the CEO's total beneficial ownership of 267,814 shares consists entirely of direct holdings, with no shares reported in indirect accounts or other share classes.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-10) | $125.81 |
| Market Capitalization | $12.5 billion |
| Revenue (TTM) | $6.2 billion |
| Net Income (TTM) | $621.0 million |
Company Snapshot
- Encompass Health Corporation operates a diversified post-acute healthcare platform delivering inpatient rehabilitation services and home health and hospice care across the United States through both dedicated facilities and in-home settings.
- The company generates revenue through its two primary divisions: Inpatient Rehabilitation, which provides focused recovery treatment on an inpatient and outpatient basis, and Home Health and Hospice, which delivers care services directly to patients in their residences.
- Encompass Health serves patients transitioning from acute care settings, including those recovering from significant illnesses, surgeries, and injuries, with a customer base comprised of healthcare systems, insurance providers, and individual patients requiring post-acute care services.
Encompass Health Corporation is a leading operator in the post-acute healthcare sector with a market capitalization of $12.5 billion and TTM revenues of $6.2 billion, positioning the company as a significant provider of rehabilitation and home-based care services. The company's diversified business model across inpatient facilities and home health services provides revenue stability and exposure to the growing demand for post-acute care driven by an aging population and the shift toward value-based care delivery. With over 40,000 employees and a strong net income margin of approximately 10% on TTM revenues, Encompass Health maintains operational scale and profitability in a fragmented market characterized by consolidation opportunities.
What this transaction means for investors
Tarr didn't have shares withheld for taxes here, and there's no plan noted; he chose to sell, and he parted with about 39% of his direct stake in a single stretch, a meaningful cut for a sitting CEO. He did it days after Encompass Health's stock jumped on strong earnings, near a 52-week high, so he sold into strength. He still holds around 268,000 shares worth more than $33 million, which keeps him well aligned, but a sale this size deserves noting rather than dismissing.
That said, the sale doesn't appear to signal trouble at the company. Encompass reported earlier this month that revenue rose about 10% to $1.6 billion, raised its full-year guidance for the second time this year, and lifted both its dividend and buyback authorization to $1 billion. Demand for its rehabilitation hospitals keeps climbing as the population ages, and in the earnings release, Tarr said the company was "very pleased with our second quarter results."
Ultimately, the most likely read here is a CEO taking some money off the table after a strong run, not a warning, though a steep cut is worth watching for whether more follows.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.